Reports and guidance documents; availability, etc.: Indwelling blood gas analyzers; premarket notification (510(k)) submissions,

[Federal Register: November 22, 2000 (Volume 65, Number 226)]


[Page 70357-70358]

From the Federal Register Online via GPO Access []



Food and Drug Administration

[Docket Nos. 00D-1557 and 00D-1558]

Guidance Documents for Premarket Notification (510(k)) Submissions for Indwelling Blood Gas Analyzers; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of two guidance documents. These two guidance documents are intended to serve as special controls for three devices that FDA has proposed previously to reclassify from class III (premarket approval) to class II (special controls). Elsewhere in this issue of the Federal Register, FDA is reopening the comment period on the proposed reclassification of the three devices. FDA is now inviting comment on these two guidance documents because they were not available for comment at the time of the publication of the proposed reclassification.

DATES: Submit written comments on the agency guidances by February 20, 2001.

ADDRESSES: Submit written comments on the agency guidances to the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Comments should be identified with the docket number for the appropriate guidance document found in table 1. Submit written requests for single copies on a 3.5" diskette of one or both of these guidance documents to the Division of Small Manufacturers Assistance (HFZ-220), Center for Devices and Radiological Health, Food and Drug Administration, 1350 Piccard Dr., Rockville, MD 20850. Send two self-addressed adhesive labels to assist that office in processing your request, or fax your request to 301-443- 8818. See the SUPPLEMENTARY INFORMATION section for information on electronic access to the guidance documents.

FOR FURTHER INFORMATION CONTACT: Joseph M. Sheehan, Center for Devices and Radiological Health (HFZ-215), Food and Drug Administration, 1350 Piccard Dr., Rockville, MD 20850, 301-827-2974.


  1. Background

    In the Federal Register of March 15, 1999 (64 FR 12774), FDA published a proposed rule to reclassify 38

    [[Page 70358]]

    preamendments class III devices into class II and to establish special controls for these devices. FDA invited interested persons to comment on the proposed rule by June 14, 1999. FDA received one request to reopen the comment period for six devices. The request noted that FDA had not made the guidance documents that were proposed as special controls for these six devices available for comment through FDA's good guidance practices (GGP's) (65 FR 56468, September 19, 2000). The request further noted that it was impossible to comment on the proposed reclassification without the guidance documents being available. Therefore, the requester asked that FDA extend the comment period until at least 90 days after the guidance documents are publicly available. FDA agreed with the request. FDA also identified three additional devices for which the agency had not issued the guidance documents proposed as special controls in accordance with the GGP policy. These three devices are the Indwelling Blood Carbon Dioxide Partial Pressure (Pco2) Analyzer (21 CFR 868.1150), the Indwelling Blood Hydrogen Ion Concentration (pH) Analyzer (21 CFR 868.1170), and the Indwelling Blood Oxygen Partial Pressure (P02) Analyzer (21 CFR 868.1200).

    The agency is announcing the availability of the two guidance documents (with separate docket numbers) for these three additional devices; the guidance documents, with their docket numbers, and Facts- on-Demand (FOD) numbers are as follows:

    Table 1.

    Name of Guidance

    Docket Number

    Facts-on-Demand Number

    Guidance for Indwelling Blood Gas Analyzer 510(k)


    1126 Submissions Guidance for Electrical Safety, Electromagnetic


    1161 Compatibility and Mechanical Testing for Indwelling Blood Gas Analyzer Premarket Notification Submissions

  2. Significance of Guidance Documents

    These guidance documents represent the agency's current thinking on premarket notifications for these devices. These guidance documents do not create or confer any rights for or on any person and do not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the applicable statute, regulations, or both. Under FDA's GGP policy, each of these guidance documents is a Level 2 guidance.

  3. Electronic Access

    In order to receive these guidance documents via your fax machine, call the CDRH FOD system at 800-899-0381 or 301-827-0111 from a touch- tone telephone. Press 1 to enter the system. At the second voice prompt press 1 to order a document. Enter the document number listed above followed by the pound sign (#). Follow the remaining voice prompts to complete your request. Persons interested in obtaining a copy of these guidance documents may do so by using the Internet. CDRH maintains an entry on the Internet for easy access to information including text, graphics, and files that may be downloaded to a personal computer with access to the Internet. Updated on a regular basis, the CDRH home page includes these guidance documents, device safety alerts, Federal Register reprints, information on premarket submissions (including lists of approved applications and manufacturers' addresses), small manufacturers' assistance, information on video conferencing and electronic submissions, mammography matters, and other device-oriented information. The CDRH home page may be accessed at cdrh.


    Interested persons may submit to the Dockets Management Branch (address above) written comments regarding these guidance documents by February 20, 2001. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number for the guidance document as listed in table 1. If you wish to comment on more than one guidance document, please submit your comments separately for each guidance document. The guidance documents and received comments may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

    Dated: October 31, 2000. Linda S. Kahan, Deputy Director for Regulations Policy, Center for Devices and Radiological Health.

    [FR Doc. 00-29840Filed11-21-00; 8:45 am]

    BILLING CODE 4160-01-F

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT